

Lifestyle Drugs 2017 Global Market Expected to Grow at CAGR Of 2.87% and Forecast To 2021

Wiseguyreports.Com Publish New Market Research Report On-"Lifestyle Drugs 2017 Global Market Expected to Grow at CAGR Of 2.87% and Forecast To 2021".

PUNE, INDIA, May 4, 2017 /EINPresswire.com/ --

[Lifestyle Drugs Market](#) 2017

About Lifestyle Drugs Market

Lifestyle disease is associated with the way an individual or group of people live. Some of the lifestyle diseases include depression, sexual dysfunction, anti-aging, baldness, and obesity.

The analysts forecast the global lifestyle drugs market to grow at a CAGR of 2.87% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global lifestyle drugs market for 2017-2021. To calculate the market size, the report considers sales of lifestyle drugs in the market.

The market is divided into the following segments based on geography:

- Americas
- EMEA
- APAC

Request a Sample Report @ <https://www.wiseguyreports.com/sample-request/1095102-global-lifestyle-drugs-market-2017-2021>



The report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

- Allergan
- BMS
- Eli Lilly
- Pfizer

Other prominent vendors

- Acerus Pharmaceuticals
- Alkermes
- Amorepacific
- AndroScience
- Anterios
- AstraZeneca
- Avanir Pharmaceuticals
- Avolynt
- Celtaxsys
- Cerecor
- Corcept Therapeutics
- Cosmo Pharmaceuticals
- CTC Bio
- Dermira
- Dong-A ST
- Euthymics Bioscience
- Foamix
- Follicum
- Forendo Pharma
- Futura Medical Developments
- Galderma
- Hanmi Pharmaceutical
- Incyte
- Intrepid Therapeutics
- Ion Channel Innovations
- iX Biopharma
- Johnson & Johnson
- Legacy Healthcare
- LEO Pharma

- H. Lundbeck
- Luye America Pharmaceuticals
- Merck
- Minerva Neurosciences
- MSI Methylation Sciences
- Neuralstem
- Novan
- Novartis
- Novo-Nordisk
- Palatin Technologies
- Paratek Pharmaceuticals
- Photocure
- Revance Therapeutics
- Rhythm Pharmaceuticals
- S1 Biopharma
- Sage Therapeutics
- Samumed
- Sanofi
- Sigma-Tau Pharmaceuticals
- Strategic Science & Technologies
- Sumitomo Dainippon Pharma
- Takeda
- TetraLogic Pharmaceuticals
- TherapeuticsMD
- Valeant Pharmaceuticals
- VistaGen Therapeutics
- VIVUS
- XBiotech
- Yuhan
- Zafgen

Market driver

- Lifestyle changes
- For a full, detailed list, view our report

Market challenge

- Patent expiries
- For a full, detailed list, view our report

Market trend

- Increase in M&A
- For a full, detailed list, view our report

Key questions answered in this report

- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Complete Report Details @ <https://www.wiseguyreports.com/reports/1095102-global-lifestyle-drugs-market-2017-2021>

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

Key market highlights

PART 05: An overview of lifestyle diseases

PART 06: Market landscape

Market overview

Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by therapy area

Depression

Dermatology (acne, anti-aging, and baldness)

Sexual dysfunction

Obesity

PART 09: Geographical segmentation

Lifestyle drugs market in Americas

Lifestyle drugs market in EMEA

Lifestyle drugs market in APAC

PART 10: Market drivers

Lifestyle changes
Development of novel therapeutics
Increasing demand from older population

PART 11: Impact of drivers

PART 12: Market challenges
Patent expiries
Side effects coupled with product recalls
Presence of alternative therapies and treatments

PART 13: Impact of drivers and challenges

PART 14: Market trends
Increase in M&A
Growing focus on development of drugs for new indications
Emerging lifestyle diseases

PART 15: Vendor landscape
Competitive scenario

PART 16: Key vendor analysis
Allergan
BMS
Eli Lilly
Pfizer
.....Continued

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1095102

Norah Trent
Wise Guy Consultants Pvt. Ltd.
+1 (339) 368 6938 (US)/+91 841 198 5042 (IND)
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/379308118>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.